Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: Linvoseltamab is Safe and Works · Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) Trial sites expanded: 21 → 24 locations Regeneron PharmaceuticalsPhase 1/2 NCT06292780
  2. Minor: IMG-007 · Moderate-to-Severe Atopic Dermatitis Trial sites expanded: 30 → 33 locations Inmagene LLCPhase 2 NCT07037901
  3. Minor: Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE) Trial sites expanded: 20 → 26 locations Alpha Cognition, IncPhase 4 NCT07633470
  4. Minor: If an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, · Advanced Malignant Tumors Trial sites expanded: 76 → 79 locations BioNTech SEPhase 1/2 NCT07070232
  5. Minor: NBI-1065890 Versus Placebo · Tardive Dyskinesia Trial sites expanded: 35 → 48 locations Neurocrine BiosciencesPhase 2 NCT07365462
  6. Minor: Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Trial sites expanded: 276 → 279 locations Spyre Therapeutics, Inc.Phase 2 NCT07012395
  7. Minor: GTX-B001 in Healthy Subjects and · Chronic Inducible Urticaria Trial sites expanded: 3 → 6 locations Granular Therapeutics LimitedPhase 1 NCT07181369
  8. Minor: 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors Trial sites expanded: 8 → 12 locations Zai Lab (Shanghai) Co., Ltd.Phase 1 NCT07374848
  9. Minor: PF-08165784 · PIK3CA-Mutated Advanced or Metastatic Solid Tumors Trial sites expanded: 0 → 5 locations PfizerPhase 1 NCT07897721
  10. Minor: REGN17235 · Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation Trial sites expanded: 0 → 3 locations Regeneron PharmaceuticalsPhase 1 NCT07753148
  11. Minor: COVER PATCH CAPTEUR PROTECT Support Solutions for Continuous Glucose Monitoring Sensors · Diabetes Trial sites expanded: 7 → 10 locations CAPTEUR PROTECTNot applicable NCT07018180
  12. Minor: SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI) Trial sites expanded: 24 → 27 locations Supira MedicalNot applicable NCT07296744
  13. Minor: Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib · High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Trial sites expanded: 258 → 262 locations National Cancer Institute (NCI)Phase 3 NCT07391774
  14. Minor: Non-Interventional Study · Limbal Stem Cell Deficiency Trial sites expanded: 8 → 21 locations Claris Biotherapeutics, Inc.Not specified NCT07636590
  15. Minor: Drug-Eluting Registry · Real-World Treatment of Lesions in the Peripheral Vasculature Trial sites expanded: 86 → 89 locations Boston Scientific CorporationNot specified NCT04674969
  16. Minor: Tornier Perform™ Reversed Monopost Study Trial sites expanded: 0 → 3 locations Stryker Trauma and ExtremitiesNot specified NCT07764614
  17. Minor: Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery Trial sites expanded: 4 → 11 locations Aesculap AGNot specified NCT05966961
  18. Minor: Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer · a Weakened Immune System Trial sites expanded: 57 → 60 locations National Cancer Institute (NCI)Phase 2 NCT07042295
  19. Minor: Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Trial sites expanded: 22 → 27 locations National Cancer Institute (NCI)Phase 2 NCT07504588
  20. Minor: Experimental Approach · Plasma Cell Leukemia, The QUANTUM Trial Trial sites expanded: 11 → 14 locations National Cancer Institute (NCI)Phase 2 NCT07605416
  21. Minor: Addition of Iberdomide to Therapy · Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Trial sites expanded: 3 → 7 locations National Cancer Institute (NCI)Phase 1/2 NCT07437963
  22. Minor: Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) Trial sites expanded: 149 → 152 locations National Cancer Institute (NCI)Phase 2 NCT06577441
  23. Minor: Histotripsy x Pancreatic Cancer Enrollment increased: 20 → 25 participants The University of Hong KongNot applicable NCT07873606
  24. Minor: Use of Ultrasound for Early Identification of Patients at Risk of Swallowing Disorders Acquired in the ICU Enrollment increased: 100 → 110 participants Centre Hospitalier Universitaire DijonNot applicable NCT05922085
  25. Minor: Vanguard Study: Testing a New Way to Screen for Cancer Trial sites expanded: 44 → 49 locations National Cancer Institute (NCI)Not applicable NCT06995898